# US 10,369,128 B1 · Pharmaceutical composition containing a cis-diamine platinum thione complex

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,128 B1
- Document ID: US10369128B1
- Status: Granted
- Kind: B1
- Application number: 16/273,986
- Filed: 2019-02-12
- Published: 2019-07-18
- Granted: 2019-08-06
- Earliest claimed: 2017-10-26
- Assignees: King Fahd University of Petroleum and Minerals
- Applicants: King Fahd University of Petroleum and Minerals
- Inventors: Mohammed Yagoub Jomaa; Anvarhusein A. Isab
- Web page: https://patentgrep.com/patent/US10369128B1

## CPC

- A61K 31/282: Platinum compounds
- A61K 31/095: Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K 31/4164: 1,3-Diazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 33/243: Platinum; Compounds thereof
- C07F 15/0013: {without a metal-carbon linkage}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A method for treating a proliferative disease, disorder, or condition comprising administering a cis-diamine platinum(II) thione complex. A cis-diamine platinum(II) thione complex and compositions containing it.

## Claims

### Claim 1

A pharmaceutical composition comprising at least one cis-diamine platinum(II) thione complex in combination with at least one pharmaceutically acceptable carrier or excipient,
wherein the cis-diamine platinum(II) thione complex is at least one selected from the group consisting of:
cis-[Pt(NH3)2(Imt)2].2NO3(1),
cis-[Pt(NH3)2(MeImt)2].2NO3(2),
cis-[Pt(NH3)2(Me2Imt)2].2NO3(3),
cis-[Pt(NH3)2(Et2Imt)2].2NO3(4),
cis-[Pt(NH3)2(PrImt)2].2NO3(5),
cis-[Pt(NH3)2(iPrImt)2].2NO3(6),
cis-[Pt(NH3)2(iPr2Imt)2].2NO3(7),
cis-[Pt(NH3)2(Diaz)2].2NO3(8),
cis-[Pt(NH3)2(EtDiaz)2].2NO3(9), and
cis-[Pt(NH3)2(Diap)2].2NO3(10),
wherein Imt is imidazolidine-2-thione, MeImt is N-methylimidazolidine-2-thione, Me2Imt is N,N′-dimethylimidazolidine-2-thione, Et2Imt is N,N′-diethylimidazolidine-2-thione, PrImt is N-propylimidazolidine-2-thione, iPrImt is N-(isopropyl)imidazolidine-2-thione, iPr2Imt is N,N′-(di-isopropyl)imidazolidine-2-thione, Diaz is diazinane-2-thione, and Diap is 1,3-Diazepane-2-thione.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 that further comprises another anticancer drug, chemotherapeutic agent, or immunopotentiator.